Charles Schwab Investment Management Inc. Boosts Stake in Guardant Health, Inc. (NASDAQ:GH)

Charles Schwab Investment Management Inc. boosted its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,016,533 shares of the company’s stock after buying an additional 13,395 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Guardant Health were worth $31,055,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GH. Wellington Management Group LLP lifted its stake in Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after buying an additional 1,137,482 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Guardant Health during the 3rd quarter worth approximately $21,389,000. Lord Abbett & CO. LLC acquired a new stake in shares of Guardant Health during the 3rd quarter worth approximately $15,624,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Guardant Health by 52.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock worth $27,007,000 after buying an additional 406,500 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. The Goldman Sachs Group lifted their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a report on Friday, February 21st. Canaccord Genuity Group lifted their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. Piper Sandler lifted their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Finally, Barclays began coverage on shares of Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $48.40.

Guardant Health Trading Up 5.5 %

Guardant Health stock opened at $42.89 on Monday. The stock has a market cap of $5.29 billion, a P/E ratio of -12.05 and a beta of 1.50. The company has a fifty day simple moving average of $43.01 and a 200-day simple moving average of $32.94. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.